Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study

Authors :: T. Macarulla Mercade
Beloo Mirakhur
F. de Jong
Andrea Wang-Gillam
G. Lakatos
L.-T. Chen
Kiheon Lee
Source :: Annals of Oncology. 29:ix63
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
Pancreatic ductal adenocarcinoma
business.industry
Internal medicine
medicine
Liposomal Irinotecan
In patient
Hematology
business
Gemcitabine
medicine.drug

Full Text Access

Tools